(R)-methyl 6,8-difluorochroman-3-ylcarbamate | 1034000-36-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: (R)-methyl 6,8-difluorochroman-3-ylcarbamate
• 英文别名: methyl N-[(3R)-6,8-difluorochroman-3-yl]carbamate；methyl N-[(3R)-6,8-difluoro-3,4-dihydro-2H-chromen-3-yl]carbamate
• CAS: 1034000-36-6
• 化学式: C₁₁H₁₁F₂NO₃
• 分子量: 243.21
• InChiKey: TZCLAZJPZGHFBN-MRVPVSSYSA-N

物化性质

• 沸点：
  353.1±42.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (R)-methyl 6,8-difluorochroman-3-ylcarbamate 在 copper(l) iodide 、 水 、 溴 、 potassium carbonate 、 potassium hydroxide 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 二甲基亚砜 为溶剂， 反应 34.0h， 生成 ethyl 6,8-difluoro-3-hydroxy-2H-chromene-4-carboxylate
  参考文献：
  名称：

  Process Research for Multikilogram Production of Etamicastat: A Novel Dopamine β-Hydroxylase Inhibitor

  摘要：

  In order to develop a manufacturing route to etamicastat, three synthetic approaches to the pivotal chiral 3-aminochroman intermediate have been studied as well as four methods for the construction of the 2-aminoethyl imidazolethione fragment. The evolution of the synthetic strategy based on the early discovery route was described. By focusing on the use of readily available starting materials it was possible to avoid chromatography steps and expensive reagents, bringing about significant improvements in cost and throughput. The best route involves construction of the chiral centre by asymmetric hydrogenation.

  DOI：

  10.1021/op300012d
• 作为产物：
  描述：

  3,5-二氟水杨醛 在 三乙烯二胺 、 sodium hypochlorite 、 硫酸 、 氢气 、 sodium hydroxide 作用下， 以 甲醇 、 溶剂黄146 为溶剂， 25.0~100.0 ℃ 、3.0 MPa 条件下， 反应 61.0h， 生成 (R)-methyl 6,8-difluorochroman-3-ylcarbamate
  参考文献：
  名称：

  Process Research for Multikilogram Production of Etamicastat: A Novel Dopamine β-Hydroxylase Inhibitor

  摘要：

  In order to develop a manufacturing route to etamicastat, three synthetic approaches to the pivotal chiral 3-aminochroman intermediate have been studied as well as four methods for the construction of the 2-aminoethyl imidazolethione fragment. The evolution of the synthetic strategy based on the early discovery route was described. By focusing on the use of readily available starting materials it was possible to avoid chromatography steps and expensive reagents, bringing about significant improvements in cost and throughput. The best route involves construction of the chiral centre by asymmetric hydrogenation.

  DOI：

  10.1021/op300012d

文献信息

• [EN] PROCESSES FOR PREPARING MEDICAMENTS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND INTERMEDIATES FOR USE THEREIN<br/>[FR] PROCÉDÉS DE PRÉPARATION DE MÉDICAMENTS POUR LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES ET INTERMÉDIAIRES PRÉVUS À CET EFFET
  申请人：BIAL PORTELA & CA SA

  公开号：WO2015038022A1

  公开（公告）日：2015-03-19

  The present invention provides a compound of formula N wherein: X is CH2, oxygen or sulphur; R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-ß-hydroxylase.

  本发明提供了一个公式为N的化合物，其中：X为CH2、氧或硫；R1、R2和R3相同或不同，表示氢、卤素、烷基、烷氧基、羟基、硝基、烷基羰基氨基、烷基氨基或二烷基氨基基团，其中N以单一的R-和S-对映体形式存在，或者是(R)-和(S)-对映体的混合物。本发明还提供了一个公式为MA的化合物。本发明还提供了制备上述化合物的方法，以及涉及它们使用的方法。这些化合物在外周选择性多巴胺-ß-羟化酶抑制剂的合成中特别有用。
• Process
  申请人：Learmonth David Alexander

  公开号：US20110112303A1

  公开（公告）日：2011-05-12

  A process for preparing the S or R enantiomer of a compound of formula A, the process comprising subjecting a compound of formula B to asymmetric hydrogenation in the presence of a chiral transition metal catalyst and a source of hydrogen, wherein X is CH 2 , oxygen, or sulphur; R 1 , R 2 and R 3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino, or dialkylamino group; and R 4 is alkyl or aryl, wherein the transition metal catalyst comprises a chiral ligand having the formula wherein p is from 1 to 6, and Ar means aryl group; wherein the term alkyl means hydrocarbon chains, straight or branched, containing from one to six carbon atoms, optionally substituted by aryl, alkoxy, halogen, alkoxycarbonyl or hydroxycarbonyl groups; the term aryl means an aromatic or heteroaromatic group, optionally substituted by alkyloxy, halogen, or nitro group; and the term halogen means fluorine, chlorine, bromine, or iodine.

  一种制备化合物A的S或R对映体的方法，该方法包括将化合物B置于手性过渡金属催化剂和氢源存在下进行不对称氢化，其中X为CH2、氧或硫；R1、R2和R3相同或不同，表示氢、卤素、烷基、烷氧基、羟基、硝基、烷基羰基氨基、烷基氨基或二烷基氨基；R4为烷基或芳基，其中过渡金属催化剂包括具有以下结构的手性配体，其中p为1至6，Ar表示芳基；其中术语烷基指的是含有一至六个碳原子的烃链，直链或支链，可选择地被芳基、烷氧基、卤素、烷氧羰基或羟基羰基基团取代；术语芳基指的是芳香或杂芳基团，可选择地被烷氧基、卤素或硝基基团取代；术语卤素指的是氟、氯、溴或碘。
• Processes for Preparing Medicaments for the Treatment of Cardiovascular Diseases and Intermediates for Use Therein
  申请人：Bial - Portela & CA., S.A.

  公开号：US20160221981A1

  公开（公告）日：2016-08-04

  The present invention provides a compound of formula N wherein: X is CH 2 , oxygen or sulphur; R 1 , R 2 and R 3 are the same or different and signify hydrogens, halogens, alkyl, alkyloxy, hydroxy, nitro, alkylcarbonylamino, alkylamino or dialkylamino group, wherein N is in the form of the individual R- and S-enantiomer or a mixture of the (R)- and (S)-enantiomer. The present invention also provides a compound of formula MA. The present invention also provides processes for preparing the above compounds, and processes involving their use. The compounds are particularly useful as intermediates in the synthesis of peripherally-selective inhibitors of dopamine-β-hydroxylase.

  本发明提供了一个化合物的公式N，其中：X是CH2，氧或硫；R1、R2和R3相同或不同，表示氢、卤素、烷基、烷氧基、羟基、硝基、烷基羰基氨基、烷基氨基或二烷基氨基基团，其中N以单个R-和S-对映体或(R)-和(S)-对映体的混合物形式存在。本发明还提供了一个化合物的公式MA。本发明还提供了制备上述化合物的方法以及涉及它们使用的方法。这些化合物在外周选择性多巴胺-β-羟化酶抑制剂的合成中特别有用。
• Process for preparing 1, 3-Dihydroimidazole-2-Thione Derivatives
  申请人：Beliaev Alexander

  公开号：US09346751B2

  公开（公告）日：2016-05-24

  The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.

  本发明涉及一种制备(R)-5-(2-(苄基氨基)乙基)-1-(6,8-二氟色曼-3-基)-1H-咪唑-2(3H)-硫醇及其药学上可接受的盐，特别是盐酸盐的方法。本发明还涉及一种制备该化合物中间体的方法，并涉及该中间体本身。
• Process for preparing 1,3-dihydroimidazole-2-thione derivatives
  申请人：BIAL-PORTELA & CA, S.A.

  公开号：US10059696B2

  公开（公告）日：2018-08-28

  The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se.

  本发明涉及一种制备(R)-5-(2-(苄基氨基)乙基)-1-(6,8-二氟苯并二氢吡喃-3-基)-1H-咪唑-2(3H)-硫酮及其药学上可接受的盐，特别是盐酸盐的工艺。本发明还涉及一种用于形成上述化合物的中间体的制造工艺，以及中间体本身。